Clinical Chemistry 45:8(B)
1377–1383 (1999)                                                                               ...
1378                                               Kaplan: Diagnosis of Thyroid Disease

Clinical Chemistry 45, No. 8(B), 1999                                             1379

“direct”, free-T4 assays (12 )....
1380                                          Kaplan: Diagnosis of Thyroid Disease

follicular lesions without further ...
Clinical Chemistry 45, No. 8(B), 1999                                                                 1381

1382                                                     Kaplan: Diagnosis of Thyroid Disease

    Some thyroid disease...
Clinical Chemistry 45, No. 8(B), 1999                                                     1383

variations of healthy t...
Upcoming SlideShare
Loading in …5

Clinical Perspectives in the Diagnosis of Thyroid Disease


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Clinical Perspectives in the Diagnosis of Thyroid Disease

  1. 1. Clinical Chemistry 45:8(B) 1377–1383 (1999) Beckman Conference Clinical Perspectives in the Diagnosis of Thyroid Disease Michael M. Kaplan Background: The wide array of available thyroid diag- pathophysiology; limitations in sensitivity, specificity, nostic tests can help provide accurate diagnoses for most and diagnostic accuracy of the tests; or a misunderstand- cases of thyroid disease but can be confusing and costly ing of the meaning of results. Clinical findings can and when used inappropriately. must be integrated with thyroid diagnostic testing to yield Methods: Published articles were reviewed and com- accurate and efficient answers to questions pertinent to bined with the author’s clinical experience and data the diagnosis and treatment of thyroid patients. Three collected from patients. types of diagnostic tests will be considered in this report: Results: The discussions focus on confusing aspects of blood tests performed in the clinical chemistry and im- thyroid diagnostic tests, the use and limitations of the munology laboratories, imaging techniques, and fine- thyrotropin test to screen for thyroid dysfunction, bio- needle biopsies. logical factors that complicate the interpretation of this and other thyroid diagnostic tests, and a combined Screening for Thyroid Disease clinical and laboratory approach to (a) thyroid diseases Because most clinical manifestations of thyroid dysfunc- with only one important dimension (“simplex” condi- tion are nonspecific (1 ), and some asymptomatic patients tions) and (b) thyroid diseases with several important have thyroid abnormalities that can cause adverse health dimensions (“multiplex” conditions). effects (2–7 ), the high-sensitivity serum thyrotropin [thy- Conclusion: The optimal use of thyroid diagnostic tests roid-stimulating hormone (TSH)1] test is often performed is patient-specific and depends on the patient’s specific on a screening basis when there is a low pre-test proba- thyroid disease, the stage of disease, and coexisting bility of disease (2–5 ). It is an excellent screening test medical conditions. because its negative predictive value is very high and the © 1999 American Association for Clinical Chemistry vast majority of results are negative (8 ). However, screen- ing is not the same as diagnosis, and abnormal TSH Several tests are available to evaluate a patient whose values can occur in patients other than those with thyroid gland is obviously abnormal or whose symptoms straightforward new cases of hyperthyroidism and hypo- or physical signs raise the possibility of thyroid disease. thyroidism (Table 2) (9 ). In addition, because of the When used and interpreted appropriately, these diagnos- log-linear relationship between serum TSH and free thy- tic tools can identify the abnormality in nearly every case, roxine (T4) concentrations (10 ), interpatient differences in but many factors contribute to suboptimal usage of thy- the slope of the log[TSH] vs [free T4] line (10 ) and the roid tests in clinical practice. At a trivial level, test great variability in analytical sensitivity of currently avail- nomenclature can be confusing (Table 1): some tests have able TSH assay methods in the range below normal, the similar names but measure different analytes, and the severity of a thyroid hormone excess or deficiency cannot same test may have different names (free thyroxine in- be determined from the TSH value alone. Therefore, when dex “T7”; antithyroid microsomal antibody anti- a patient with nonspecific symptoms and physical find- thyroid peroxidase). However, most of the difficulty in ings has an abnormal serum TSH concentration, the most thyroid diagnosis stems from more substantive causes: appropriate response is further evaluation to verify that complexities in the biology of thyroid physiology and there is a thyroid abnormality and, if so, determination of its cause and severity. Particular caution is necessary in screening hospital- Associated Endocrinologists, 6900 Orchard Lake Road, Suite 203, West Bloomfield, MI 48322, and Departments of Medicine and Nuclear Medicine, William Beaumont Hospital, Royal Oak, MI 48073. Fax 248-855-5628; e-mail 1 Nonstandard abbreviations: TSH, thyrotropin (thyroid-stimulating hor- Received March 8, 1999; accepted May 4, 1999. mone); T4, thyroxine; T3, triiodothyronine; and CT, computed tomography. 1377
  2. 2. 1378 Kaplan: Diagnosis of Thyroid Disease majority of patients do not have clinically significant Table 1. Confusing thyroid test nomenclature. thyroid disease (11 ). Possible intended meanings [incorrect meanings Test name sometimes encountered] Free T4 Free-T4 index (or “T7”) Utility and Limitations of Thyroid Diagnostic Tests Free T4 concentration For patients with abnormal serum TSH concentrations, T3 Serum total T3 concentration, serum free T3 follow-up consists of a focused history, physical exami- concentration, T3-uptake test to assess T4 nation with special attention to the thyroid gland, a repeat binding to serum proteins TSH test for verification, determination of serum thyroid Thyroglobulin Serum thyroglobulin concentration, [anti-thyroglobulin antibody test], hormone concentrations, and sometimes, imaging studies. [thyroxine-binding globulin] Unfortunately, it is not unheard of for patients to be told Uptake test T3- (or T4-) uptake test to assess T4 binding to that because they have high TSH concentrations, they serum proteins, radioiodine uptake by the thyroid need to take thyroid medication lifelong and be sent a gland, “uptake scan”, i.e., thyroid scintiscan combined with thyroid radioiodine uptake prescription for T4 without further workup or explana- measurement tion. Moreover, because goitrous changes in the thyroid Anti-thyroid Anti-thyroglobulin antibody, anti-thyroperoxidase (or gland or the development of thyroid nodules often do not antibody anti-microsomal) antibody, anti-TSH-receptor alter thyroid function, a TSH concentration within the antibody, antibody against the thyrocyte Na/I symporter, [anti-mitochondrial antibody] reference interval in a patient with one of these structural abnormalities provides only part of the necessary infor- mation and does not mean that the patient’s thyroid ized and other severely ill patients for thyroid disease. condition is innocuous. Full evaluation of these cases Severe nonthyroid illness, whether physical or psychiat- requires some combination of antithyroid antibody tests, ric, and drugs such as glucocorticoids or dopamine can imaging, and fine-needle biopsy. change the behavior of the pituitary-thyroid axis to cause Patients with abnormal TSH results should have serum abnormally high or low serum TSH values in the absence thyroid hormone determinations. Because 99% of T4 of thyroid disease, as judged by follow-up studies after and triiodothyronine (T3) in the blood are bound to serum patients have recovered from their nonthyroid illnesses proteins, but only the free thyroid hormones are biologi- (11 ). In the absence of an abnormal thyroid gland by cally active, estimates of free thyroid hormone concentra- careful physical examination, a hospital inpatient with a tions are theoretically preferable to total-T4 and total-T3 mild or moderate ( 20 mIU/L) increase in serum TSH tests. A 1991 report from the American Thyroid Associa- and an estimated free T4 (by either a free-T4 test or a tion summarized the performance of different types of free-T4 index) within the health-related reference interval free-T4 and free-T3 assays (12 ), and there have been no can usually be followed without treatment and reevalu- major changes since then. Free-T4 index methods can be ated later. The same holds true for a patient with a used successfully if their limitations and performance in subnormal serum TSH and estimated free T4 and serum various clinical settings are understood, but they may be T3 values that are not increased. In both cases, the great more subject to false-positive results than other, more Table 2. Some causes of abnormal serum TSH concentrations. TSH below normal TSH above normal Primary hyperthyroidism Primary hypothyroidism Pituitary/hypothalamic disease with central hypothyroidism Pituitary thyrotroph adenoma Pituitary resistance to thyroid hormone (central hyperthyroidism) Generalized thyroid hormone resistance Prolonged thyrotroph cell suppression after recent hyperthyroidism Thyrotoxicosis from overly rapid correction of severe hypothyroidism with in euthyroid or hypothyroid patient parenteral T4 Old age Old age Drugs, e.g., glucocorticoids, dopamine Drugs, e.g., amiodarone Problems with T4 treatment Problems with T4 treatment Overdosage in treatment for fatigue or overweight Underdosage based on misleadingly high total T4 Altered gastrointestinal absorption because of drugs or disease Altered gastrointestinal absorption because of drugs or disease Altered T4 clearance because of drugs Altered T4 clearance because of drugs Patient compliance problems Patient compliance problems Prescription error Prescription error Testing too soon after T4 dose decrease Testing too soon after T4 dose increase Many severe systemic illnesses Recovery phase after severe systemic illness Combination of pulsatile TSH secretion and analytical precision Combination of pulsatile TSH secretion and analytical precision limits limits Antibody in patient serum against antibody in TSH assay, causing analytical artifact
  3. 3. Clinical Chemistry 45, No. 8(B), 1999 1379 “direct”, free-T4 assays (12 ). Free-T3 assays are available, Table 3. Biological pitfalls in thyroid test interpretation. but are not often used. Binding protein abnormalities can Blood tests increase total T3 in the absence of hyperthyroidism, nota- Anomalous binding of T4 or T3 to serum proteins bly during estrogen treatment and pregnancy. If neces- Genetic sary, a T-uptake test or thyroxine-binding globulin mea- Drug induced surement can be used to calculate a free-T3 index, or a Disease induced free-T3 test can be obtained to clarify an ambiguous Pregnancy increased total-T3 result. Altered reference intervals for thyroid hormones or TSH When hypothyroidism is suspected, a free-T4 estimate Childhood is appropriate because total-T3 and free-T3 tests have Pregnancy inadequate sensitivity and specificity in this setting. When Old age hyperthyroidism is suspected, the combination of a Disrupted set point of the hypothalamic-pituitary-thyroid axis free-T4 estimate and a total- or free-T3 estimate provides Nonthyroid illness the most complete assessment of the severity of hyperthy- Drugs roidism and identifies cases of “T3-toxicosis”, i.e., a selec- Thyroid hormone resistance tive increase of the serum T3 concentration. In some Acute psychiatric illness centers, free-T4 and -T3 tests are routinely used when the Imaging tests TSH is increased (8 ), but in others, serum T3 measure- High radioiodine uptake by the thyroid gland without ments are obtained only when the TSH is low and the free hyperthyroidism (“hypertrapping”) Hashimoto thyroiditis with normal or low thyroid function T4 is within the reference interval. I prefer to monitor both Congenital thyroperoxidase deficiency serum free T4 and T3 in patients with low serum TSH Antithyroid drugs (other than hypothyroid patients taking T4), even after the Low radioiodine uptake by the thyroid gland without thyroid diagnosis is known, to establish patterns of in- hypothyroidism creasing or decreasing values over time. In patients with Hyperthyroid phase of subacute and postpartum thyroiditis subclinical hyperthyroidism or those treated with antithy- Exposure to high concentrations of nonradioactive iodine roid drugs, identification of a temporal trend can be quite Altered thyroid parenchymal sonographic texture in Hashimoto valuable in deciding when to initiate or modify therapy, thyroiditis as illustrated in the case report below. Multiple focal changes difficult to distinguish from colloid Biological factors that can cause confusing thyroid nodules or neoplasms Very high prevalence of nonpalpable nodules 1 cm in middle- diagnostic test results are listed in Table 3. Such results aged and elderly individuals when ultrasound thyroid imaging frequently generate patient referrals to my associates and is performed myself and can inappropriately raise patients’ hopes or Cytology fears. The first two blood test categories in Table 3 Continuum of cytologic features in benign and well-differentiated represent non-disease. Children with learning disorders follicular neoplasms have been referred to me because of serum T3 concentra- Inconclusive or suspicious thyroid fine-needle biopsy cytology tions above a laboratory’s stated reference interval, with a serum TSH concentration within the reference interval. The parents have been told that either hyperthyroidism or mm hypoechoic areas (15 )—with no mention of Hashi- thyroid hormone resistance (13 ) is the problem and that I moto disease as the most likely diagnosis, but with a will solve the problem by treating the thyroid. Instead, the summary stating only that any one of the focal changes children have serum T3 concentrations within the age- might be a cancer. The ultrasound finding of one or two appropriate reference intervals (14 ), but the laboratory nonpalpable thyroid nodules 1 cm in diameter with reports a reference interval that actually applies only to regular borders and no calcifications is another non- nonpregnant adults with no other medical problems. The disease, because an enormous number of people have parents of these children are always disappointed, and them, and the chances of a clinically significant cancer in sometimes are frustrated and angry. There are also age- such lesions are so small that observation is considered and pregnancy-related changes in the reference intervals appropriate management (16 –18 ). It is a disservice to the for serum total T4, free T4, TSH, and thyroxine-binding patient and the primary physician for the ultrasound globulin (14 ). report to comment about this type of lesion only that Imaging tests are also subject to misinterpretation “cancer cannot be ruled out”, but I encounter such reports (Table 3). It is common to receive a report describing a often and only rarely see a more appropriate comment thyroid radioactive iodine uptake value in the “hyperthy- such as, “this is a nonspecific finding found in more than roid range” or “hypothyroid range”, although thyroid half of all individuals over age 60” (19 ). secretory function cannot accurately be inferred from this In the evaluation of thyroid nodules by fine-needle test. Another problem is a thyroid ultrasound report that biopsy, up to 20% of cases have findings of a cellular describes the typical features of Hashimoto thyroiditis— follicular lesion for which malignancy cannot be excluded coarse texture of the parenchyma and multiple focal 1– 6 (Table 3) (20 ). Some cytopathologists report these as
  4. 4. 1380 Kaplan: Diagnosis of Thyroid Disease follicular lesions without further comment. Other experi- Approximately 90% of the cases of hypothyroidism enced cytopathologists feel that they can subdivide this shown in Table 4 were attributable to Hashimoto thyroid- type of lesion into risk categories with chances of cancer itis, but again, for the 10% with other diagnoses the ranging from 5–10% to 50% (20 ). Having a specific optimal management may differ. A patient who has had degree of cancer risk may help in the decision between radioiodine ablation for hyperthyroidism may require an surgery and observation for the patient who has an unusually low dose of T4 because of autonomous function increased risk of surgical complication because of age or in the thyroid remnant. In patients taking T4 for hypothy- coexisting illness. This information can also help the roidism caused by Hashimoto thyroiditis, many factors surgeon decide on the extent of resection (20 ). can alter a patient’s dose requirement (21, 22 ), and pa- tients with problems in T4 treatment are referred to me Simplex Thyroid Diseases with some regularity (Tables 2 and 4). Thyroid diseases with a single important dimension can In patients with diffuse euthyroid goiters (Table 4), be termed “simplex” conditions. Examples are hypothy- those with negative antithyroid antibody tests (almost roidism with mild, diffuse thyroid enlargement; hyper- one-half) are more likely to have autonomous function thyroid Graves disease without ophthalmopathy; or a and a future risk of hyperthyroidism, whereas those with solitary thyroid nodule. Simplex does not, however, nec- positive antibody tests ( 43%) have a greater likelihood essarily imply that optimal clinical management is simple. of future hypothyroidism (23 ). A recent study suggested Table 4 presents the diagnoses of new patients in my that levothyroxine treatment to shrink thyroid nodules is practice, during a 1-year period, who had hyperthyroid- more likely to succeed in patients with Hashimoto thy- ism, hypothyroidism, or euthyroid goiter. When the eval- roiditis than in patients with no evidence of autoimmu- uation of hyperthyroidism included antithyroid antibody nity (24 ). tests and scintiscanning, Graves disease accounted for If the prognosis and appropriate management of pa- 86% of cases. The other 14% had diagnoses for which tients with Hashimoto thyroiditis differ from those of management differs from that of Graves disease, e.g., in patients with non-autoimmune conditions, we should be the appropriate dose of radioactive iodine, the possibility able to detect thyroid autoimmunity reliably. The diag- of ethanol ablation for a single toxic autonomous nodule, nostic sensitivity of available antithyroid antibody test or the advisability of observation because of the self- methods may vary. One study (25 ) suggested that mea- limited nature of the disease. surement of only the anti-thyroid peroxidase (or “anti- microsomal”) antibody suffices because almost no pa- tients have increased concentrations of the anti- Table 4. Causes of hyperthyroidism, hypothyroidism, and thyroglobulin antibody alone (Table 5). However, using a euthyroid goiter in consecutive patients new to the different method to measure the anti-thyroglobulin anti- author’s practice in 1 year (1991). body and possibly testing a patient population selected Diagnosis n % differently, I found substantially more patients with an Hyperthyroidism 120 100 isolated increase of anti-thyroglobulin antibody than an Graves disease 103 85.8 isolated increase of anti-microsomal antibody (Table 5). Toxic multinodular goiter 7 5.8 Therefore, the conclusion that performing both antithy- Single toxic adenoma 4 3.3 Subacute or postpartum thyroiditis 4 3.3 roid antibody tests “increases the cost without an offset- Pituitary resistance to thyroid hormone 1 0.8 ting diagnostic gain” (25 ) may be limited to specific Hyperemesis gravidarum 1 0.8 methods and/or patient populations. It would seem pre- Hypothyroidism 260 100 mature to advise a universal abandonment of the anti- Hashimoto thyroiditis, new 123 47.3 thyroglobulin antibody test. Hashimoto thyroiditis, treated Another simplex condition is a solitary thyroid nodule. Euthyroid 58 22.3 The diagnostic evaluation is straightforward: check the Undertreated 28 10.8 TSH and do a needle biopsy (16, 17 ). Management prob- Overtreated 25 9.6 lems arise from the 5–20% of cases in which the biopsy Spontaneous, antibody-negative 10 3.8 specimens are insufficient for diagnosis and the addi- Post radioiodine, untreated 9 3.5 tional 20% for which the cytology is ambiguous (20 ). In Antithyroid drug overdose 1 0.4 those cases, we must use other clinical risk factors in Iodine overload or lithium therapy 3 1.2 deciding about surgery (26 –28 ). Even for nodules with Generalized thyroid hormone resistance 3 1.2 benign cytology, controversy persists regarding the value Euthyroid goiter 255 100 of suppressive treatment with T4 (29 ). Diffuse, antibody-negative 122 47.8 Thus, even in simplex thyroid diseases, many patients Diffuse, Hashimoto thyroiditis 110 43.1 benefit from an evaluation beyond the first-line tests. Multinodular 16 6.3 Welcome developments on the laboratory front would be Compensatory, post surgery 5 2.0 better standardization of tests such as antithyroid anti- Lithium therapy 2 0.8 bodies, free T4, and free T3 to allow results from different
  5. 5. Clinical Chemistry 45, No. 8(B), 1999 1381 Table 5. Comparative utility of anti-thyroid antibody tests in relation to patient population and test methods. Agglutination method for anti- thyroglobulina RIA method for anti-thyroglobulinb Anti-thyroid microsomal Anti-thyroglobulin % of 700 % of 139 antibody antibody n positives n positives Negative Negative 1330 161 Positive Positive 185 26 87 63 Positive Negative 507 72 9 6 Negative Positive 8 1 43 31 Total 2030 300 a Data for the agglutination anti-thyroglobulin method are those of Nordyke et al. (25) on consecutive patients referred to a clinic and hospital laboratory, most “on suspicion or presence of Hashimoto’s thyroiditis, a goiter, hypothyroidism, or Graves’ disease”, using the Ames Sera-Tek kit (Ames Division, Miles Inc., Diagnostics Division). b Data for the RIA anti-thyroglobulin method are from consecutive patients, referred to my office, who had findings suggesting the same conditions or other causes of hyperthyroidism and for whom the anti-thyroglobulin antibody was measured by RIA (33), using a kit from Kronus. In both sets of data, the anti-thyroid microsomal antibody was assayed by the Ames Sera-Tek agglutination kit. laboratories to be interpreted similarly. In addition, the high index of suspicion and sufficient experience to application of new techniques, such as PCR amplification recognize atypical combinations of test results and clinical of tumor marker genes, to fine-needle biopsy samples findings, unusual patterns of test results, per se, or would help reduce the uncertainty about cellular follicu- unexpected responses of patients to usual treatments. It is lar lesions and further reduce the number of patients not rare for Graves disease and Hashimoto thyroiditis to operated on for benign thyroid nodules. occur in the same patient, and some patients with this combination spontaneously progress from hyperthyroid- Multiplex Thyroid Diseases ism to hypothyroidism. The reverse sequence also occurs, More complicated problems, with two or more important but far less often. It is even rarer for a patient to cycle up dimensions, can be designated “multiplex” thyroid con- and down more than once. Lymphoma can arise within ditions. Examples are listed in Table 6. The general the thyroid gland, usually against a background of Hashi- categories include coexisting diseases, single diseases that moto thyroiditis (30 ), presumably because of malignant can cause several types of complications, and diseases transformation of one or more of the inflammatory cells. that evolve through several phases. Focal swelling or a generalized increase in thyroid size The identification of coexisting conditions requires a despite adequate levothyroxine replacement justifies cy- tological or surgical evaluation for lymphoma, and con- sultation between the clinician and the cytopathologist Table 6. Examples of multiplex thyroid diseases. before a needle biopsy allows the pathologist to arrange Coexisting unrelated conditions for the specimens to be specially processed for evaluation Hashimoto thyroiditis follicular cell neoplasm of possible lymphoma. Serum T4 and T3 protein-binding anomalies true thyroid dysfunction In the thyroid diseases with several possible complica- Coexisting related diseases tions (Table 6), the investigation of one aspect of the Hashimoto thyroiditis Graves disease disease can have implications for other aspects. An ex- Hashimoto thyroiditis and lymphoma ample is a large multinodular goiter with autonomous Diseases with several possible complications function. Potential problems are tracheal narrowing, in- Goiter: tracheal or esophageal compression, thyroid dysfunction, terference with swallowing, hyperthyroidism, and a dis- unacceptable appearance figuring neck mass. Computed tomography (CT) is some- Nodule: cancer risk, unacceptable appearance times necessary to evaluate the possibility of tracheal or Graves disease: hyperthyroidism, eye abnormalities esophageal compression. However, if a CT contrast agent Diseases that evolve over weeks to months is used, the thyroid is exposed to high concentrations of Subacute or postpartum thyroiditis: thyroid function, size, and stable iodine, which may cause iodine-induced thyrotox- discomfort all change icosis and prevent ablative treatment with radioiodine. Hemorrhage into a nodule: pain and swelling can vary Diseases that evolve over years Once again, communication between physicians is vital, Autonomously functioning adenoma: regression, infarction, in this case between the clinician and the radiologist. increase in size function Although contrast-enhanced CT images are sharper, it is Simple goiter: increase in size, function, nodularity easy to identify the tracheal air column and obtain a Graves disease in remission: many patients ultimately become satisfactory assessment of thyroid size and geometry by a hypothyroid non-contrast CT scan. When informed of thyroid abnor- Thyroid cancer: slow progression of residual disease or late malities in patients, radiologists are happy to arrange recurrences non-contrast studies.
  6. 6. 1382 Kaplan: Diagnosis of Thyroid Disease Some thyroid diseases evolve through several phases laboratories that used different instruments or kits to (Table 6). Medically appropriate, cost-effective use of measure serum free T4, it would have been difficult, if not diagnostic tests differs depending on whether the patient impossible, to discern the trend toward hyperthyroidism. is at the stage of initial diagnosis, in a disease phase in The imaging studies shown in Fig. 1 established the which future change is expected, or under treatment diagnosis of an autonomous nodule rather than Graves requiring therapeutic monitoring. In addition, clinical and disease, and this information was used to select a rela- laboratory findings from each check-up must be viewed tively high therapeutic dose of radioiodine because toxic in the context of sequential test results over time. nodular goiters are more radioresistant than Graves dis- Fig. 1 shows the progressive increase in secretory ease thyroid glands (31 ). activity of an autonomously functioning thyroid adenoma Another test in which the pattern of sequential test in a woman who was 45 years of age at the time of initial results can be more important than single values is the evaluation. The serum TSH initially was within the refer- serum thyroglobulin concentration, used as a tumor ence interval, and the contralateral lobe continued to marker in the long-term follow-up of patients who have function. After 3 years, the TSH was suppressed, as was had thyroid cancer. However, currently available serum the function of the extranodular thyroid tissue. However, thyroglobulin assays have wide intermethod variability in the serum free T4 was in the lower half of the reference results and analytical sensitivity, suboptimal interassay range, the patient felt fine, and the nodule was unobtru- precision even when only one method is used, and for sive. By 1997, she was menopausal and the serum free T4 some methods, susceptibility to “hook” effects that had increased, but she had no hyperthyroid symptoms greatly underestimate very high values (32 ). and no cosmetic problems. The serum free-T3 concentra- tions (not shown) paralleled the serum free-T4 results. Conclusion Radioiodine ablative treatment was administered in 1997 The appropriate use of thyroid diagnostic tests varies because the progressive increase in serum free T4, with according to the clinical setting: screening for thyroid concentrations that predicted the development of overt dysfunction, initial evaluation of an abnormal clinical or hyperthyroidism within several years, and because the laboratory finding, management of simplex thyroid dis- persistently high-normal thyroid hormone concentrations eases, elucidation of the components of multiplex thyroid after 1994 could predispose her to postmenopausal osteo- diseases, long-term follow-up of evolving abnormalities, porosis (7 ). This treatment decision was not based on the or monitoring of patients’ responses to treatment. Reduc- last free-T4 result or any other single test value. If sequen- tion in needless evaluation of thyroid non-disease can tial tests had been performed using a mixture of free-T4 potentially be achieved by improvements in test nomen- index and free-T4 concentration values or in different clature, test standardization, and the understanding of Fig. 1. Evolution of an autonomously functioning thyroid adenoma. The graph shows serum free-T4 concentrations between 1989 and 1997. The thickened portion of the y-axis is the reference interval. The arrow denotes the time of administration of radioactive iodine ablative therapy. The upper image is a pertechnetate thyroid scintigram from 1989, showing persistent function in the left lobe; the lower image is a pertechnetate scintigram from 1992, when the serum TSH was first suppressed, showing negligible tracer uptake in the left lobe. The TSH concentration remained suppressed thereafter.
  7. 7. Clinical Chemistry 45, No. 8(B), 1999 1383 variations of healthy thyroid function and structure. Com- Levy EG, et al. Treatment guidelines for patients with thyroid munication among the clinician, the clinical pathologist, nodules and well-differentiated thyroid cancer. Arch Intern Med and the radiologist greatly increases the value of diagnos- 1996;156:2165–72. 17. Feld S, Garcia M, Baskin HJ, Cobin RH, Gharib H, Hay ID, et al. tic tests. In all but the most straightforward cases of T4 AACE clinical practice guidelines for the diagnosis and manage- treatment of hypothyroidism, the combination of clinical ment of thyroid nodules. Endocr Pract 1996;2:78 – 84. findings with test results is vital in determining the best 18. Tan GH, Gharib H. Thyroid incidentalomas: management ap- management plan for the patient. Test results alone, proaches to nonpalpable nodules discovered incidentally on thy- however sophisticated and accurate, often do not suffice. roid imaging. Ann Intern Med 1997;126:226 –31. 19. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl References J Med 1993;328:553–9. 1. Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of 20. Hamburger JI, Kaplan MM. Evaluation of thyroid nodules by needle hypothyroidism correlate with biochemical disease? J Gen Intern biopsy. In: Braverman LE, Utiger RD, eds. Werner and Ingbar’s the Med 1997;12:544 –50. thyroid. A fundamental and clinical text. Philadelphia: Lippincott- 2. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Raven, 1996:447– 60. Daniels G, et al. Treatment guidelines for patients with hyperthy- 21. Kaplan MM. Thyroid hormone therapy. What, when and how much. roidism and hypothyroidism. JAMA 1995;273:808 –12. Postgrad Med 1993;93:249 – 62. 3. Garcia M, Baskin HJ, Feld S, Cobin RH, Daniels GH, Davidson ET, 22. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med et al. AACE clinical practice guidelines for the evaluation and 1995;333:1688 –94. treatment of hyperthyroidism and hypothyroidism. Endocr Pract 23. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in 1995;1:54 – 62. the elderly. Microsomal antibodies as discriminant for therapy. 4. American College of Physicians. Screening for thyroid disease. JAMA 1987;258:209 –13. Ann Intern Med 1998;129:141–3. 24. Benvenga S, Alesci S, Arico CN, Trimarchi F. The effect of ` 5. Helfand M, Redfern CC. Screening for thyroid disease: an update. thyrotropin (TSH) suppressive L-thyroxine (T4) therapy in thyroid Ann Intern Med 1998;129:144 –58. nodularity of Hashimoto’s thyroiditis [Abstract]. Program of the 6. Cooper DS. Subclinical thyroid disease: a clinician’s perspective 71st Annual Meeting of the American Thyroid Association, Port- [Editorial]. Ann Intern Med 1998;129:135– 8. land, OR. New York. The American Thyroid Association, 1998:23. 7. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. 25. Nordyke RA, Gilbert FI, Miyamoto LA, Fleury KA. The superiority of Endocrinol Metab Clin N Am 1998;27:37– 49. antimicrosomal over antithyroglobulin antibodies for detecting 8. Klee GG, Hay ID. Biochemical testing of thyroid function. Endocri- Hashimoto’s thyroiditis. Arch Intern Med 1993;153:862–5. nol Metab Clin N Am 1997;26:763–75. 26. Belfiore A, LaRosa GL, LaPorta GA, Giuffrida D, Milazzo G, Lupo L, 9. Scanlon MF, Toft AD. Regulation of thyrotropin secretion. In: et al. Cancer risk in patients with cold thyroid nodules: relevance Braverman LE, Utiger RD, eds. Werner and Ingbar’s the thyroid. A of iodine intake, sex, age, and multinodularity. Am J Med 1992; fundamental and clinical text. Philadelphia: Lippincott-Raven, 93:363–9. 1996:220 – 40. 27. Schlinkert RT, van Heerden JA, Goellner JR, Gharib H, Smith SL, 10. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, et Rosales RF, Weaver AL. Factors that predict malignant lesions al. Applications of a new chemiluminometric thyrotropin assay to when fine-needle aspiration is “suspicious for follicular neo- subnormal measurements. J Clin Endocrinol Metab 1990;70: plasm”. Mayo Clin Proc 1997;72:913– 6. 453– 60. 28. Tuttle MR, Lemar H, Burch HB. Clinical features associated with 11. Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in an increased risk of thyroid malignancy in patients with follicular hospitalized patients. A systematic review. Arch Intern Med 1999; neoplasia by fine-needle aspiration. Thyroid 1998;8:377– 83. 159:658 – 65. 12. Hay ID, Bayer MF, Kaplan MM, Klee GG, Larsen PR, Spencer CA. 29. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with American Thyroid Association assessment of current free thyroid levothyroxine for solitary thyroid nodules: a double-blind controlled hormone and thyrotropin measurements and guidelines for future clinical study and cumulative meta-analyses. J Clin Endocrinol clinical assays. Clin Chem 1991;37:2002– 8. Metab 1998;83:3881–5. 13. Hauser P, Zametkin AJ, Martinez P, Vitiello B, Matochik JA, Mixson 30. Hamburger JI, Miller JM, Kini SR. Lymphoma of the thyroid. Ann AJ, Weintraub BD. Attention deficit-hyperactivity disorder in people Intern Med 1983;99:685–93. with generalized resistance to thyroid hormone. N Engl J Med 31. Kaplan MM, Meier DA, Dworkin HJ. Treatment of hyperthyroidism 1993;328:997–1001. with radioactive iodine. Endocrinol Metab Clin N Am 1998;27: 14. Fisher DA. The Quest diagnostics manual. Endocrinology test 205–23. selection and interpretation, 2nd ed. San Juan Capistrano, CA: 32. Spencer CA, Takeuchi M, Kazarosyan M. Current status and Quest Diagnostics Nichols Institute, 1998:333pp. performance goals for serum thyroglobulin assays. Clin Chem 15. Solbiati L, Charboneau JW, James EM, Hay ID. The thyroid gland. 1996;42:164 –73. In: Rumack CM, Wilson SR, Charboneau JW, eds. Diagnostic 33. Beever K, Bradbury J, Phillips D, McLachlan SM, Pegg C, Goral A, ultrasound. St. Louis: Mosby, 1998:703–29. et al. Highly sensitive assays of autoantibodies to thyroglobulin 16. Singer PA, Cooper CS, Daniels GH, Ladenson PW, Greenspan FS, and to thyroid peroxidase. Clin Chem 1989;35:1949 –54.